| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5590817 | Multiple Sclerosis and Related Disorders | 2017 | 40 Pages |
Abstract
In Japanese RRMS patients, natalizumab treatment every 4 weeks for 24 weeks was well tolerated and reduced the development of new brain lesions and relapses (Funded by Biogen; ClinicalTrials.gov identifier: NCT01440101).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Takahiko Saida, Jun-ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, JT Tibung, Nisha Lucas, Meena Subramanyam, On behalf of Natalizumab Trial Principal Investigators On behalf of Natalizumab Trial Principal Investigators,